Knowing the immunotype of the AD patients, therapeutic plans may be more precise in treatment and more effective with new biological agents like dupilumab (anti IL4R monoclonal antibody) and more like new biological antibodies blocking the IL-13, IL-22, and IL-17. This evidence concerns the gene IL22 and Alzheimer disease.